Based on the 2003 NCI review, and in consultation with CUMC and NYPH leadership,- and the newly constituted External Scientific.Advisory Board, the HICCC Director outlined a Strategic Plan to restructure and expand the Center.. The Plan included reshaping HICCC Leadership via internal promotions and recruitments and building active internal and external advisory bodies for the HICCC. This plan was successfully implemented with the recruitment of the Deputy Director for Clinical Research (Dr. E. Gelmann), the Associate Director for Biomedical Informatics (Dr. A. Califano), and the internal promotions of the Associate Director for Basic Research (Dr. R. Baer), the Associate Director for Shared Resources (Dr. Benjamin Tycko), and the Associate Director for Population Science (Dr. A. Neugut). In addition, three of the present seven HICCC Programs are led by newly nominated faculty. This reorganization of leadership has been accompanied by an overhaul of Planning and Evaluation and by the redesign of the HICCC's internal and external advisory bodies. The HICCC Director has the responsibility and authority to set priorities and to develop new Programs; nominate and retain scientific leaders and members;select programs, projects and members to receive pilot funding;allocate HICCC resources;'and organize the HICCC as a whole to promote productivity and scientific interactions. The Deputy Director for Clinical Research assists the HICCC Director in accomplishing these goals and in organizing the HICCC's clinical activities. The Director's decisions are based on input from the internal and external advisory bodies. The main internal advisory bodies include: i) the Senior Leadership Team;ii) the Internal Advisory Committee;iii) the Space Committee;iv) the Membership Committee;. and v) the Shared Resource Committee. The External Scientific Advisory Board (ESAB) has been reorganized in its leadership and composition, currently including 11 members representative of the major areas of HICCC research and administration. Funding in the amount of $16,500 is requested for the annual meeting of the ESAB.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA013696-36
Application #
7862532
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
36
Fiscal Year
2009
Total Cost
$23,832
Indirect Cost
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Sones, Jennifer L; Merriam, Audrey A; Seffens, Angelina et al. (2018) Angiogenic factor imbalance precedes complement deposition in placentae of the BPH/5 model of preeclampsia. FASEB J 32:2574-2586
Park, Karen Sophia; Xu, Christine L; Cui, Xuan et al. (2018) Reprogramming the metabolome rescues retinal degeneration. Cell Mol Life Sci 75:1559-1566
Mumau, Melanie D; Vanderbeck, Ashley N; Lynch, Elizabeth D et al. (2018) Identification of a Multipotent Progenitor Population in the Spleen That Is Regulated by NR4A1. J Immunol 200:1078-1087
Savage, Thomas M; Shonts, Brittany A; Obradovic, Aleksandar et al. (2018) Early expansion of donor-specific Tregs in tolerant kidney transplant recipients. JCI Insight 3:
Caviglia, Jorge Matias; Yan, Jun; Jang, Myoung-Kuk et al. (2018) MicroRNA-21 and Dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis. Hepatology 67:2414-2429
Jauregui, Ruben; Park, Karen Sophia; Tsang, Stephen H (2018) Two-year progression analysis of RPE65 autosomal dominant retinitis pigmentosa. Ophthalmic Genet 39:544-549
Wu, Wen-Hsuan; Tsai, Yi-Ting; Justus, Sally et al. (2018) CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinitis Pigmentosa: A Brief Methodology. Methods Mol Biol 1715:191-205
Yen, Bonnie; Fortson, Katherine T; Rothman, Nyanza J et al. (2018) Clonal Bifurcation of Foxp3 Expression Visualized in Thymocytes and T Cells. Immunohorizons 2:119-128
Ishida, Chiaki T; Zhang, Yiru; Bianchetti, Elena et al. (2018) Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma. Clin Cancer Res 24:5392-5406
Jin, Chun-Hui; Li, Yang; Xia, Jinxing et al. (2018) CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion. Am J Hematol 93:786-793

Showing the most recent 10 out of 331 publications